Actueel promotieonderzoek

Een overzicht van de lopende promotieonderzoeken van apothekers. Deze zijn geïnventariseerd bij de verschillende onderzoeksgroepen in het land. Zo is inzichtelijk wie er met welk onderwerp bezig is. De KNMP actualiseert de lijst jaarlijks.

New medicines: what is their clinical value

Geneesmiddelregulering

Studie over nieuwe geneesmiddelen die op de makrt komen: wat is hun klinische waarde, hoe worden ze voorgeschreven.

2019 - 2022

Universiteit: Groningen
Promovendus: Marloes Dankers
Promotor(es): Liset van Dijk,
Aukje Mantel
Co-promotor(es): Marjorie Nelissen

Healthcare professionals’ views on clinical relevance of new medicines in primary care

Geneesmiddelregulering

New medicines are evaluated by registration authorities in order to assess their benefit-risk-balance. However, not every new medicine has to have an added therapeutic value compared to already available medicines. The real clinical relevance of new medicine is therefore sometimes unclear. In this research project, we want to investigate the views of healthcare professionals (HCPs) on clinical relevance of new medicines in primary care. We will discuss healthcare professionals’ views on clinical relevance of new COPD and T2DM medicines and also describe the reasons for prescribing new medicines, which is often not in line with guideline recommendations. Finally, we want to investigate how healthcare professionals assess the clinical relevance of medicines that obtained market access in the last years, and to investigate which pharmaceutical gaps (in other words: which diseases cannot be properly treated and would demand new therapies) HCPs identify in their daily practice. 

2019 - 2023

Universiteit: Groningen
Promovendus: Marloes Dankers
Promotor(es): prof. dr. Liset van Dijk,
prof. dr. Aukje Mantel-Teeuwisse
Co-promotor(es): dr. Marjorie Nelissen

Early approval of medicines (in the EU): levels of knowledge, uncertainties and risks

Geneesmiddelregulering

Understand differences in levels of knowledge, uncertainties and risks at approval for medicines that receive early vs. regular approval; to assess the added value of data requested by regulators to resolve uncertainties in the post-approval phase and to determine the possible consequences of accepted uncertainties and risks.

2016 - 2020

Universiteit: Utrecht
Promovendus: Lourens Bloem
Promotor(es): Aukje Mantel,
Olaf Klungel
Co-promotor(es): Jarno Hoekman,
Menno vd Elst

Drug Regulatory Science

Geneesmiddelregulering

Universiteit: Utrecht
Promovendus: Jet Scheffers
Promotor(es): Leufkens
Co-promotor(es): Gardarsdottir

Access to medicines in low and middle income countries – effects and alignment of pharmaceutical policies

Geneesmiddelregulering

Universiteit: Utrecht
Promovendus: Iris Joosse
Promotor(es): Mantel,
Suleman
Co-promotor(es): van den Ham

Safety assessment and use of biologicals/ biosimilars in clinical practice

Geneesmiddelregulering

The aim of this project is to provide insight in the use of biologicals, including biosimilars, in clinical practice and add to the safe and effective use of these agents. We also provide guidance on the implementation of biosimilars in clinical practice from the perspective of different stakeholders including prescribers, pharmacists and patients.

2018 - 2022

Universiteit: Utrecht
Promovendus: Rosanne Meijboom
Promotor(es): Toine Egberts,
Bert Leufkens
Co-promotor(es): Thijs Giezen,
Helga Gardarsdottir

Contact

Wetenschappelijke Adviesraad (WAR)
Martina Teichert

(070) 373 72 31 war@knmp.nl